Guthoff R, Haase J, von Domarus D, Draeger J, Lauritzen K
Universitäts-Augenklinik Hamburg.
Klin Monbl Augenheilkd. 1990 Jan;196(1):6-10. doi: 10.1055/s-2008-1046119.
The present paper reports on follow-up examinations of 246 patients after Ruthenium106 treatment of choroidal melanomas (follow-up time 1.8 to 13 years). In January 1988, 212 patients were alive and free of metastases; 15 had died, 12 of them of melanoma metastases, and 17 could not be followed up. In a retrospective analysis of factors influencing tumor-related mortality, the rate of regression of irradiated tumors was found to be particularly significant. The mean time taken to reduce tumor volume by half was 4.4 months in patients who died of metastases, as against 6.6 months in a matched group of survivors. Using discriminance analysis, the difference was found to be highly significant (P = 0.0058). In the total patient population, a significant correlation was found between pretreatment tumor volume and the probability of metastases (P = 0.058). It may be concluded, though with the qualification that the number of tumor-related deaths was small, that the tumor regression rate is an important factor in the prognosis for patients with Ruthenium-treated malignant choroidal melanomas.
本文报道了246例脉络膜黑色素瘤经钌106治疗后的随访检查情况（随访时间为1.8至13年）。1988年1月，212例患者存活且无转移；15例患者死亡，其中12例死于黑色素瘤转移，17例无法进行随访。在对影响肿瘤相关死亡率的因素进行回顾性分析时，发现照射肿瘤的消退率尤为显著。死于转移的患者将肿瘤体积减半所需的平均时间为4.4个月，而匹配的存活组患者为6.6个月。通过判别分析，发现差异具有高度显著性（P = 0.0058）。在全部患者群体中，发现治疗前肿瘤体积与转移概率之间存在显著相关性（P = 0.058）。尽管肿瘤相关死亡病例数较少，但可以得出结论，肿瘤消退率是钌治疗的恶性脉络膜黑色素瘤患者预后的一个重要因素。
